CardioComm Solutions, Inc.

CardioComm Solutions, Inc.

March 25, 2011 19:32 ET

CardioComm Solutions, Inc. Enters into Investor Relations Agreement

VICTORIA, BRITISH COLUMBIA--(Marketwire - March 25, 2011) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") today announced that it has entered into an investor relations agreement with ARTÉMIA™ Communications, Inc. ("Artemia") of San Francisco, California, under which Artemia will provide comprehensive investor relations services on behalf of CardioComm, including: drafting, revising and disseminating press releases, investor presentations and investor materials; responding to shareholder inquiries; and introducing CardioComm to strategic members in the financial and investment sectors.

Under the terms of the agreement, Artemia will provide the services for the 2011 calendar year, receiving a fee of US$7,000 per month; provided, however, that no fee shall be payable by CardioComm unless and until CardioComm raises at least Cdn$1,000,000 in financing from external sources, at which point all accrued fees will be payable. CardioComm will also reimburse Artemia for all reasonable expenses incurred by Artemia in providing the services.

Founded in 1995, ARTÉMIA™ Communications, Inc. is an integrated full-service communications agency committed to delivering a tangible return on investment to a diverse group of North American, European and Asian clients. Headquartered in San Francisco, and led by its founder Barbara I. Wichmann, Artemia and its affiliates have broad expertise in emerging industries and technologies, and are particularly focused upon healthcare IT and healthcare, high-tech (wireless, mobile, SaaS and hardware), renewable energy/clean-tech utilities and financial services. Artemia does not hold a direct or indirect interest in CardioComm or its securities.

CardioComm also announced that it granted an aggregate of 650,000 incentive stock options, including 550,000 options to Simi Grosman, an independent member of the Company's board of directors. The options are exercisable at $0.10 per share for five years from the date of grant, will vest equally over a period of 18 months and are subject to a four month hold period. The grant of options will be subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

Furthermore, CardioComm announced its intention to issue 500,000 common shares to Equity Communications Ontario, Ltd. ("Equity Communications"). The shares, which will be issued at $0.06 per share, represent a fee owed by CardioComm to Equity Communications under a strategic advisory agreement between the parties. The payment of the fee by the issuance of the common shares is subject to the approval of the TSX Venture Exchange, and the shares will be subject to a four month hold period.

About CardioComm Solutions, Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Etienne Grima, CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information